Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Revenue Decline Continues in Q3 as Net Loss Widens 32 Percent

NEW YORK, Nov. 3 (GenomeWeb News) - Nanogen has reported third-quarter revenue of $1.1 million, down from $1.7 million in the comparable period a year ago.

 

The results match the revenue and related decline that the firm posted in the second quarter of 2004. Product revenue for the three months ended Sept. 30 fell to $671,000 from $752,000 for the third quarter of 2003.

 

Nanogen's net loss grew to $9.4 million, or $.28 per share, from $7.1 million, or $.33 per share, for the third quarter last year. The results include the first full quarter of activity related to its SynX subsidiary, which the firm acquired in April.

 

The San Diego-based microarray and diagnostics firm reported a slight increase in research and development spending to $4.5 million from $4.3 million in the third quarter of 2003. It finished the quarter with $53.1 million in cash, cash equivalents, and short-term investments.

 

Nanogen is in the process of acquiring Epoch Biosciences in an all-stock transaction valued at roughly $60 million. Shareholders of both firms are scheduled to vote on the merger on Dec. 8, and the merger partners expect to complete the deal by the end of the year.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.